Jump to main content
Jump to site search

Issue 8, 2014
Previous Article Next Article

Recognition of diazirine-modified O-GlcNAc by human O-GlcNAcase

Author affiliations

Abstract

The mammalian O-GlcNAc hydrolase (OGA) removes O-GlcNAc from serine and threonine residues on intracellular glycoproteins. OGA activity is sensitive to N-acyl substitutions to O-GlcNAc, with alkyl diazirine-modified O-GlcNAc (O-GlcNDAz) being completely resistant to removal by OGA. Using homology modeling, we identified OGA residues proximal to the N-acyl position of O-GlcNAc substrate. Mutation of one of these residues, C215, results in mutant enzymes that are able to hydrolytically remove O-GlcNDAz from a model compound. Further, the C215A mutant is capable of removing O-GlcNDAz from a peptide substrate. These results can be used to improve metabolism of O-GlcNAc analogs in cells. In addition, the enzyme specificity studies reported here provide new insight into the active site of OGA, an important drug target.

Graphical abstract: Recognition of diazirine-modified O-GlcNAc by human O-GlcNAcase

Back to tab navigation

Supplementary files

Publication details

The article was received on 10 Apr 2014, accepted on 30 May 2014 and first published on 02 Jun 2014


Article type: Concise Article
DOI: 10.1039/C4MD00164H
Citation: Med. Chem. Commun., 2014,5, 1227-1234
  •   Request permissions

    Recognition of diazirine-modified O-GlcNAc by human O-GlcNAcase

    A. C. Rodriguez and J. J. Kohler, Med. Chem. Commun., 2014, 5, 1227
    DOI: 10.1039/C4MD00164H

Search articles by author

Spotlight

Advertisements